Researchers from DANDRITE have played a central role in developing a new oral treatment that, for the first time ever, has ...

This open-label Phase 1 study measures safety, peripheral and central inflammation, effects on Treg cell populations, and FTD progression; Five of the 8 planned FTD subjects have been enrolled to date ...

"Vesper Bio’s FTD candidate shows progranulin increase in Phase Ib/IIa trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...

King of Prussia, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3 ...

Results of study will inform Coya’s randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage ...